Fig. 1. The experimental process of analyzing the mechanism of FN improving AD symptoms based on transcriptomics and proteomics. FN, fibrauretine; AD, Alzheimer’s disease.

Korean J Physiol Pharmacol 2024;28:361-377 https://doi.org/10.4196/kjpp.2024.28.4.361

© Korean J Physiol Pharmacol